STING
STING (stimulator of interferon genes) is an innate-immune signaling protein that functions in the cGAS–STING pathway, linking detection of cytosolic DNA—including mitochondrial DNA—to inflammatory and type I interferon responses.
STING (stimulator of interferon genes) is an innate-immune signaling protein that functions in the cGAS–STING pathway, linking detection of cytosolic DNA—including mitochondrial DNA—to inflammatory and type I interferon responses. Its activation can promote NF-κB signaling, macrophage and microglial inflammatory activity, and antitumor immunity. In experimental models, STING activation has been associated with enhanced CD8-positive T-cell infiltration, M1 macrophage polarization, and improved immune responses to vaccines and tumors, whereas excessive activation may contribute to tissue injury and neuroinflammation.
STING is therefore being investigated as a context-dependent pharmaceutical target. Agonists such as 2′,3′-cGAMP are being incorporated into lipid, polymeric, albumin-based, and hydrogel delivery systems to improve anti-infective and cancer immunotherapy, including combinations with tumor antigens, Toll-like receptor agonists, chemotherapy, pyroptosis-inducing strategies, and PARP inhibition. Conversely, STING inhibitors and PROTAC degraders are being explored for conditions involving harmful inflammation, including post-cardiac-arrest brain injury, radiation-induced hematopoietic injury, and acute kidney injury. These applications reflect efforts to achieve tissue-specific modulation of STING rather than uniform activation or blockade.
Where the papers sit
18 papers from the last 6 months study STING directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 18 preclinical
Themes 4 themes
-
STING in Cancer and Injury
Therapeutic STING modulation is being tested across cancer and tissue injury, with activation used to intensify antitumor inflammation and inhibition to limit sterile damage. In ovarian cancer, ferroportin deficiency links olaparib resistance to a cGAS-STING-STAT3 survival axis. Pyroptosis, metal hydrogels and oxygen-related stress are being paired with cGAS-STING in colorectal metastases, while nanoinhibitors target radiation injury. Neuroinflammation and macrophage or microglial polarization remain recurring endpoints.
5 papers · 27.8%
-
STING Inflammation and Injury
Small-molecule STING inhibition is moving toward orally bioavailable compounds and targeted degradation for inflammatory disease. Acute kidney injury studies emphasize mitochondrial DNA, interferon and IL-linked inflammation, including STING PROTACs and chirality-dependent toxicity. Mitophagy-STING coupling is extended to inflammatory bone loss, while AMnESTI uses STING modulation to restore age-impaired lung vaccine responses. Selectivity, safety and separation of inflammatory control from immune protection remain open.
5 papers · 27.8%
-
STING Combination Cancer Therapy
Cancer immunotherapy is moving toward combinations that restore STING signaling while supplying tumor antigen or blocking immune suppression. Lipid-conjugated vaccines, Abraxane-based STING agonist platforms and PD-L1 silencing pair innate activation with adaptive responses, especially in triple-negative breast cancer. CREBBP loss reveals epigenetic silencing of STING and MHC-I as a route to immune evasion in small cell lung cancer. PARP inhibition, including YCH1899, is being combined with STING agonists to induce type I interferon signaling in BRCA-proficient tumors.
5 papers · 27.8%
-
STING Agonist Immunotherapy
STING agonists are being engineered as immune-activating components of cancer and anti-infective therapy rather than used as unmodified agents. cGAMP liposomes, dendritic-cell nanoplatforms and T cell–agonist chimeras aim to concentrate activation in antigen-presenting or tumor-facing cells. The recurring goal is stronger CD8 T-cell priming and remodeling of the tumor microenvironment while limiting systemic exposure. Logic-gated activation and scalable delivery remain key design challenges.
3 papers · 16.7%
Papers
The 18 papers from the last 6 months that study STING directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
STING in Cancer and Injury (5)
- Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis. Clinical and translational medicine · 2 Nov 2026 PMID 42968661
- STING inhibition alleviates post-cardiac arrest brain injury by suppressing microglia-mediated neuroinflammation via the cGAS/STING/NF-κB pathway. International immunopharmacology · 4 Aug 2026 PMID 42551197
- Intelligent metal-integrated hydrogels orchestrate pyroptosis and cGAS-STING for potentiated treatment of colorectal cancer peritoneal metastasis. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456978
- A bone-marrow-homing biomimetic STING nanoinhibitor alleviates radiation-induced hematopoietic injury via modulating macrophage polarization. Journal of controlled release : official journal of the Controlled Release Society · 27 Jun 2026 PMID 42364698
- Hydroxycinnamic acids target COPII cargo sorting machinery to attenuate inflammation via the cGAS-STING axis. Journal of ethnopharmacology · 24 May 2026 PMID 42178077
STING Inflammation and Injury (5)
- Discovery of Novel Orally Bioavailable STING Inhibitors with 4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrazine Moiety for STING-Mediated Inflammatory Disorders. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018606
- AMnESTI reverses age-associated lung immune decline to drive heterosubtypic protection by inactivated influenza vaccines. Science immunology · 11 Sept 2026 PMID 42726884
- Dual-regulation of mitophagy and cytosolic mtDNA-induced inflammation for the treatment of inflammatory bone loss. Free radical biology & medicine · 18 Jul 2026 PMID 42471165
- Chirality-dependent toxicity decoupling: Discovery of a resibufogenin-based L-configured STING inhibitor with superior therapeutic profile for ulcerative colitis. European journal of medicinal chemistry · 18 Jul 2026 PMID 42470935
- Discovery of indolyl-urea compounds as effective STING PROTAC degraders for the treatment of acute kidney injury. Bioorganic chemistry · 29 Jun 2026 PMID 42372458
STING Combination Cancer Therapy (5)
- CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer. Science advances · 22 Oct 2026 PMID 42905834
- Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 17 Sept 2026 PMID 42753819
- PARP inhibitor YCH1899 activates type I interferon signaling and synergizes with STING agonists in BRCA-proficient tumors. Molecular biomedicine · 26 Aug 2026 PMID 42645640
- Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy. Cancer letters · 20 Jul 2026 PMID 42476286
- An Abraxane-based albumin nanoplatform loaded with a STING agonist for synergistic dual immunotherapy of triple-negative breast cancer. Biomaterials advances · 30 May 2026 PMID 42218104
STING Agonist Immunotherapy (3)
- Engineered T cell-agonist chimera for logic-gated STING activation and augmented cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 3 Nov 2026 PMID 42975942
- Dendritic cell centric nanoengineering couples antigen acquisition and STING activation for cancer immunotherapy. Cell reports. Medicine · 7 Sept 2026 PMID 42705236
- cGAMP-liposome: A versatile and scalable STING agonist adjuvant for enhanced anti-infective and antitumor immunity. International journal of pharmaceutics · 3 Sept 2026 PMID 42692376
By study type
Preclinical: animal, cell and lab studies (18)
- Discovery of Novel Orally Bioavailable STING Inhibitors with 4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrazine Moiety for STING-Mediated Inflammatory Disorders. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018606
- Engineered T cell-agonist chimera for logic-gated STING activation and augmented cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America · 3 Nov 2026 PMID 42975942
- Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis. Clinical and translational medicine · 2 Nov 2026 PMID 42968661
- CREBBP loss drives immune evasion by epigenetically silencing STING and MHC-I in small cell lung cancer. Science advances · 22 Oct 2026 PMID 42905834
- Thymine-functionalized bPEI nanocomplexes for synergistic STING activation and PD-L1 silencing to potentiate cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 17 Sept 2026 PMID 42753819
- AMnESTI reverses age-associated lung immune decline to drive heterosubtypic protection by inactivated influenza vaccines. Science immunology · 11 Sept 2026 PMID 42726884
- Dendritic cell centric nanoengineering couples antigen acquisition and STING activation for cancer immunotherapy. Cell reports. Medicine · 7 Sept 2026 PMID 42705236
- cGAMP-liposome: A versatile and scalable STING agonist adjuvant for enhanced anti-infective and antitumor immunity. International journal of pharmaceutics · 3 Sept 2026 PMID 42692376
- PARP inhibitor YCH1899 activates type I interferon signaling and synergizes with STING agonists in BRCA-proficient tumors. Molecular biomedicine · 26 Aug 2026 PMID 42645640
- STING inhibition alleviates post-cardiac arrest brain injury by suppressing microglia-mediated neuroinflammation via the cGAS/STING/NF-κB pathway. International immunopharmacology · 4 Aug 2026 PMID 42551197
- Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy. Cancer letters · 20 Jul 2026 PMID 42476286
- Dual-regulation of mitophagy and cytosolic mtDNA-induced inflammation for the treatment of inflammatory bone loss. Free radical biology & medicine · 18 Jul 2026 PMID 42471165
- Chirality-dependent toxicity decoupling: Discovery of a resibufogenin-based L-configured STING inhibitor with superior therapeutic profile for ulcerative colitis. European journal of medicinal chemistry · 18 Jul 2026 PMID 42470935
- Intelligent metal-integrated hydrogels orchestrate pyroptosis and cGAS-STING for potentiated treatment of colorectal cancer peritoneal metastasis. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456978
- Discovery of indolyl-urea compounds as effective STING PROTAC degraders for the treatment of acute kidney injury. Bioorganic chemistry · 29 Jun 2026 PMID 42372458
- A bone-marrow-homing biomimetic STING nanoinhibitor alleviates radiation-induced hematopoietic injury via modulating macrophage polarization. Journal of controlled release : official journal of the Controlled Release Society · 27 Jun 2026 PMID 42364698
- An Abraxane-based albumin nanoplatform loaded with a STING agonist for synergistic dual immunotherapy of triple-negative breast cancer. Biomaterials advances · 30 May 2026 PMID 42218104
- Hydroxycinnamic acids target COPII cargo sorting machinery to attenuate inflammation via the cGAS-STING axis. Journal of ethnopharmacology · 24 May 2026 PMID 42178077
Written from 18 PubMed abstracts, each one listed by PMID above. Published: 2026-10-16. Drafted by language models from published abstracts; not medical advice.